Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

NCT04794218 is registered in ClinicalTrials.gov with International AIDS Vaccine Initiative as lead sponsor.

NCT NCT04794218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04794218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath
Lead sponsor
International AIDS Vaccine Initiative
Phase
Phase 1
Overall status
Unknown status
Start date
June 23, 2021
Completion date
March 31, 2024
Enrollment
114 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lassa fever, lassa virus infection